Stragen
Ivan Cerqueira is an experienced professional in the pharmaceutical and cosmetics industries, currently serving as a Propagandista Pleno at Stragen since May 2016. Prior to this role, Ivan founded Inova Cosméticos and worked as a Senior Sales Consultant at Medley Indústria Farmacêutica, where notable achievements included the development of the Vivanza product's Orange Labels Project and the social initiative "Caravana da Alegria Medley." Ivan is recognized as a champion in both editions of Medley's Top PDV Campaign. Educationally, Ivan holds an MBA in Commercial Management and Marketing from the Business School São Paulo, completed in 2013.
This person is not in any offices
Stragen
Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.